BEIJING (Reuters) – China’s National Medical Products Administration said on Thursday that it has approved two more COVID-19 vaccines for public use.
The two vaccines are made by CanSino Biologics Inc and Sinopharm’s affiliate Wuhan Institute of Biological Product.
The new approvals meant China had four locally developed approved vaccines for COVID-19.
(Reporting by Roxanne Liu in Beijing and Meg Shen in Hong Kong; Writing by Colin Qian; Editing by Alex Richardson)
